Can pregnancy-associated plasma protein-A be a marker for the assessment of atherosclerosis risk in patients with chronic plaque psoriasis?

Basit Öğe Kaydı
dc.authorid0000-0002-4060-3354en_US
dc.authorid0000-0001-9226-5134
dc.authorid0000-0003-0203-272X
dc.contributor.authorPolat, Mualla
dc.contributor.authorBuğdaycı, Güler
dc.contributor.authorŞahin, Aslı
dc.contributor.authorKaya, Hatice
dc.contributor.authorSezer, Tuna
dc.contributor.authorÖztürk, Serkan
dc.date.accessioned2021-06-23T19:44:15Z
dc.date.available2021-06-23T19:44:15Z
dc.date.issued2016
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractIntroduction: Psoriasis is an immune-mediated chronic inflammatory dermatosis. Several studies have shown that patients with psoriasis have a much greater risk of cardiovascular diseases than the normal population. The chronic inflammation observed in psoriasis is thought to have a role in the development of atherosclerosis and vascular endothelial injury. Aim: To examine serum pregnancy-associated plasma protein-A (PAPP-A) levels, which has been regarded as a marker of early stage atherosclerosis in patients with psoriasis that do not have concurrent conventional cardiovascular risk markers. Material and methods: Forty-one patients diagnosed with a chronic plaque type of psoriasis and 42 equally matched healthy volunteers were included in this study. The PAPP-A levels were compared between patient and control groups and the association between PAPP-A levels and disease duration and severity were evaluated in the patient group. Results: Statistically, serum PAPP-A levels were significantly higher in the psoriasis group than in the control group (p = 0.015). Serum PAPP-A levels were found to be positively correlated with severity (p = 0.036, r = 0.329) and duration (p = 0.014, r = 0.269) of the disease. Conclusions: As a marker of early stage atherosclerosis, PAPP-A levels were elevated in the psoriasis group and were correlated with disease duration and severity. This elevation reveals the presence of atherosclerosis in patients with psoriasis. Further studies are needed to confirm the use of PAPP-A as an available and inexpensive screening test and cardiovascular risk assessment for all centers.en_US
dc.identifier.doi10.5114/ada.2016.62839
dc.identifier.endpage344en_US
dc.identifier.issn1642-395X
dc.identifier.issue5en_US
dc.identifier.pmid27881939en_US
dc.identifier.scopus2-s2.0-84992386184en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage340en_US
dc.identifier.urihttps://doi.org/10.5114/ada.2016.62839
dc.identifier.urihttps://hdl.handle.net/20.500.12491/8948
dc.identifier.volume33en_US
dc.identifier.wosWOS:000386539100005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorPolat, Mualla
dc.institutionauthorBuğdaycı, Güler
dc.institutionauthorŞahin, Aslı
dc.institutionauthorKaya, Hatice
dc.institutionauthorSezer, Tuna
dc.institutionauthorÖztürk, Serkan
dc.language.isoenen_US
dc.publisherTermedia Publishing House Ltden_US
dc.relation.ispartofPostepy Dermatologii I Alergologiien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPsoriasisen_US
dc.subjectPregnancy Associated Plasma Protein-Aen_US
dc.subjectAtherosclerosisen_US
dc.titleCan pregnancy-associated plasma protein-A be a marker for the assessment of atherosclerosis risk in patients with chronic plaque psoriasis?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
mualla-polat.pdf
Boyut:
131.33 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Koleksiyonu